Free account + free DSCSA compliance software — credential review typically takes 1–2 business days. See how it works
Premier Pharma Insights
Pharmacy operations

Drug Shortages: Why FDA's List Is So Much Shorter Than ASHP's, and How a Clinic Buyer Should Use Both

FDA and ASHP both track U.S. drug shortages, and their counts are far apart. They aren't contradicting each other. They define a shortage differently. Here's what each list counts, what's on them that clinics buy, and how to use both without stockpiling or buying from the wrong source.

· 6 min read

Written and clinically reviewed by Jacob Fuchs, PharmD

Reviewed on

On November 4, 2026, FDA's drug shortage database listed 69 drugs as currently in shortage (FDA Drug Shortages). ASHP's count for the third quarter of 2026 was 225 active shortages (Becker's, Oct 2026). Same country, same drug supply, about three times the number.

Neither list is wrong. They're counting different things. If you buy for a clinic, you need both, and you need to know which question each one answers.

What counts as a shortage to FDA?

The law defines a drug shortage as "a period of time when the demand or projected demand for the drug within the United States exceeds the supply of the drug" (21 U.S.C. 356c).

FDA's database marks a drug "Currently in Shortage" when the total supply of all clinically interchangeable versions isn't enough to meet current or projected demand. FDA says its program focuses on medically necessary products with a significant effect on public health. Shortages expected to resolve quickly, and shortages of a single strength or package size where a substitute exists, usually aren't its focus (FDA FAQ).

Translation: FDA lists a shortage when the country runs short, not when your usual NDC goes on backorder.

What counts as a shortage to ASHP?

ASHP's list is run with the University of Utah Drug Information Service. ASHP defines a drug product shortage as "a supply issue that affects how the pharmacy prepares or dispenses a drug product or influences patient care when prescribers must use an alternative agent" (ASHP guidelines, 2018).

That's a clinician's definition, and it casts a wider net than FDA's (Pharmacy Times). If the vial size you use disappears and you have to change how you stock or prepare the drug, that can count as a shortage to ASHP even when the national supply of the drug looks fine to FDA. According to the same report, the Utah service contacts manufacturers to verify a shortage when one is reported.

For scale: ASHP's all-time high was 323 active shortages in the first quarter of 2024. Its count was 227 in the second quarter of 2026 (AJMC, July 2026) and 225 in the third (Becker's). Better than the peak. Still not good.

Where does FDA get its information?

Mostly from manufacturers (FDA FAQ). Under section 506C of the Food, Drug, and Cosmetic Act, manufacturers of covered drugs have to notify FDA of a permanent discontinuance, or of an interruption likely to cause a meaningful disruption in supply, including problems with the active ingredient. Covered drugs are life-supporting, life-sustaining, or used to prevent or treat a debilitating disease or condition, including certain drugs used in emergency care or surgery. Notice is due at least 6 months ahead, or as soon as practicable if that isn't possible. Manufacturers also have to keep a redundancy risk management plan (21 U.S.C. 356c).

FDA also takes reports from health care professionals and patients at drugshortages@fda.hhs.gov (FDA FAQ).

What does an FDA entry actually tell you?

More than the headline. Each entry breaks down by manufacturer and presentation, with the NDC, its availability (for example, "Limited Availability" or "Unavailable"), estimated recovery or other notes, and the shortage reason the manufacturer reported (FDA Drug Shortages). One maker's NDC can be unavailable while another's is only limited.

So don't stop at the generic name. Find your NDC in the entry. If you're fuzzy on how to read one, here's our NDC guide.

FDA uses three statuses (FDA FAQ):

  • Currently in Shortage: total supply of interchangeable versions isn't meeting demand.
  • Resolved: demand is covered and manufacturers don't expect supply problems. Resolved entries stay listed for 6 months.
  • Discontinuation: a specific product is no longer being distributed. These stay listed for 1 year. A discontinuation doesn't automatically mean a shortage, since other manufacturers may still make the drug.

What's on FDA's list that clinics buy?

When we checked on November 4, 2026, FDA's "Currently in Shortage" list included these, among others (FDA Drug Shortages):

  • Lidocaine hydrochloride injection (our guide)
  • Lidocaine with epinephrine injection (our guide)
  • Bupivacaine, plain and with epinephrine
  • Ketorolac injection (our guide)
  • Dexamethasone sodium phosphate injection (our guide)
  • Methylprednisolone acetate injection (our guide)
  • Dexmedetomidine injection (our guide)
  • Midazolam, atropine, sodium bicarbonate, and sterile water for injection

That's a big piece of a typical procedure room. The list changes often, so check it yourself before you act on this one.

How should a clinic buyer use both lists?

1. Use FDA for the national picture and your exact NDC. Is the drug actually short? Which presentations? What reason did the manufacturer give? 2. Use ASHP for what clinicians are dealing with and what to do about it. FDA's own FAQ sends people to ASHP for shortage lists and suggested alternatives, because choosing an alternative is the practice of medicine, which FDA doesn't regulate (FDA FAQ). 3. Talk to your prescribers before a shortage, not during one. Which product you switch to is a clinical decision. Purchasing's job is to know what's available and bring options. 4. Don't stockpile. ASHP's guidelines say stockpiling can create artificial shortages and leaves you with expensive inventory your normal usage may never burn through. Since manufacturers often allocate product based on past purchases, a giant order usually doesn't raise your allocation anyway (ASHP guidelines). 5. Decide your sourcing rules ahead of time. ASHP's guidelines warn that product from gray-market and other nontraditional sources may be of questionable quality, and they say each organization should set its policy on these sources before a shortage hits (ASHP guidelines). When a "we have it in stock" email shows up mid-shortage, verify the seller first. Here's how to verify a pharmaceutical wholesaler.

Ask us before you scramble

Premier Pharma supplies licensed clinics, surgery centers, urgent care centers, and pharmacies, and every invoice lists the lot number and expiration date for each item. If something you buy shows up on either list, send us the NDC and we'll tell you what we can source and what we can't. Open a free account. Credential review typically takes 1–2 business days.

Sources

Written by

Jacob Fuchs, PharmD

CEO of Premier Pharma

Premier Pharma Insights

Browse all insights